Skip to content

TriangleGet started

← Full study record

NCT01844505 · OUTCOME

Mean Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) Physical Functioning

Phase 3 Study of Nivolumab or Nivolumab Plus Ipilimumab Versus Ipilimumab Alone in Previously Untreated Advanced Melanoma (CheckMate 067) · Source last updated 2025-05-21

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure: MEAN
Unit: Points on EORTC scale
Interval / dispersion: Standard Deviation
Time frame: Baseline (Day 1) and Week 5, 7, 11, 13, 17, 19, 23, 25, 31, 37, 43, 49, 55, 61, 67, 73, 79, 85, 91, 97, 103, 109, 115, 121, 127, 133, 139, 145, 151 and 157

What was measured

Health Related Quality of Life was assessed using the EORTC QLQ-C30 questionnaire Version 3. With the exception of 2 items included in the global health/quality of life scale, for which responses range from 1 (Very poor) to 7 (Excellent), item responses range from 1 (Not at all) to 4 (Very much). Raw scores for the EORTC QLQ-C30 are transformed to a 0-100 metric such that higher scores for all functional scales and Global Health Status indicate better HRQoL; an increase from baseline indicates improvement in HRQoL compared to baseline.

Analysis population: All randomized participants. Only participants with evaluable EORTC scores at baseline and at particular timepoint are considered in the analysis.

Groups in this outcome

Nivolumab

Nivolumab monotherapy 3 mg/kg intravenous (IV) once every 2 weeks (Q2W) until disease progression or unacceptable toxicity

Nivolumab + Ipilimumab

Nivolumab 1 mg/kg IV combined with Ipilimumab 3 mg/kg IV once every 3 weeks (Q3W) for 4 doses followed by nivolumab 3 mg/kg IV Q2W until disease progression or unacceptable toxicity

Ipilimumab

Ipilimumab monotherapy 3 mg/kg IV Q3W for a total of 4 doses

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

Group	Source count
Nivolumab	316
Nivolumab + Ipilimumab	314
Ipilimumab	315

Reported measurements

Week 5 (n= 233, 183, 221)

Analysis denominator · Participants

Group	Source count
Nivolumab	233
Nivolumab + Ipilimumab	183
Ipilimumab	221

Values in Points on EORTC scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Nivolumab	-2.6	13.62	Not reported	Not reported	Not reported
Nivolumab + Ipilimumab	-4.9	14.52	Not reported	Not reported	Not reported
Ipilimumab	-5.2	14.09	Not reported	Not reported	Not reported

Week 7 (n= 239, 183, 218)

Analysis denominator · Participants

Group	Source count
Nivolumab	239
Nivolumab + Ipilimumab	183
Ipilimumab	218

Values in Points on EORTC scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Nivolumab	-2.4	14.53	Not reported	Not reported	Not reported
Nivolumab + Ipilimumab	-5.3	14.92	Not reported	Not reported	Not reported
Ipilimumab	-5.1	14.69	Not reported	Not reported	Not reported

Week 11 (n= 201, 112, 163)

Analysis denominator · Participants

Group	Source count
Nivolumab	201
Nivolumab + Ipilimumab	112
Ipilimumab	163

Values in Points on EORTC scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Nivolumab	-2.4	16.14	Not reported	Not reported	Not reported
Nivolumab + Ipilimumab	-5.6	13.76	Not reported	Not reported	Not reported
Ipilimumab	-6.3	14.72	Not reported	Not reported	Not reported

Week 13 (n= 195, 106, 130)

Analysis denominator · Participants

Group	Source count
Nivolumab	195
Nivolumab + Ipilimumab	106
Ipilimumab	130

Values in Points on EORTC scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Nivolumab	-1.7	15.79	Not reported	Not reported	Not reported
Nivolumab + Ipilimumab	-4.3	14.11	Not reported	Not reported	Not reported
Ipilimumab	-5.0	17.47	Not reported	Not reported	Not reported

Week 17 (n= 158, 84, 104)

Analysis denominator · Participants

Group	Source count
Nivolumab	158
Nivolumab + Ipilimumab	84
Ipilimumab	104

Values in Points on EORTC scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Nivolumab	-1.4	15.82	Not reported	Not reported	Not reported
Nivolumab + Ipilimumab	-6.7	17.27	Not reported	Not reported	Not reported
Ipilimumab	-3.7	13.46	Not reported	Not reported	Not reported

Week 19 (n= 164, 96, 98)

Analysis denominator · Participants

Group	Source count
Nivolumab	164
Nivolumab + Ipilimumab	96
Ipilimumab	98

Values in Points on EORTC scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Nivolumab	0.4	14.14	Not reported	Not reported	Not reported
Nivolumab + Ipilimumab	-3.7	14.34	Not reported	Not reported	Not reported
Ipilimumab	-4.3	17.70	Not reported	Not reported	Not reported

Week 23 (n= 134, 86, 75)

Analysis denominator · Participants

Group	Source count
Nivolumab	134
Nivolumab + Ipilimumab	86
Ipilimumab	75

Values in Points on EORTC scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Nivolumab	0.9	13.87	Not reported	Not reported	Not reported
Nivolumab + Ipilimumab	-4.0	15.59	Not reported	Not reported	Not reported
Ipilimumab	-5.5	15.04	Not reported	Not reported	Not reported

Week 25 (n= 144, 97, 75)

Analysis denominator · Participants

Group	Source count
Nivolumab	144
Nivolumab + Ipilimumab	97
Ipilimumab	75

Values in Points on EORTC scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Nivolumab	1.4	11.02	Not reported	Not reported	Not reported
Nivolumab + Ipilimumab	-4.2	14.28	Not reported	Not reported	Not reported
Ipilimumab	-3.6	16.19	Not reported	Not reported	Not reported

Week 31 (n= 123, 92, 51)

Analysis denominator · Participants

Group	Source count
Nivolumab	123
Nivolumab + Ipilimumab	92
Ipilimumab	51

Values in Points on EORTC scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Nivolumab	1.9	11.60	Not reported	Not reported	Not reported
Nivolumab + Ipilimumab	-2.4	12.91	Not reported	Not reported	Not reported
Ipilimumab	-2.9	14.62	Not reported	Not reported	Not reported

Week 37 (n= 116, 88, 48)

Analysis denominator · Participants

Group	Source count
Nivolumab	116
Nivolumab + Ipilimumab	88
Ipilimumab	48

Values in Points on EORTC scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Nivolumab	2.1	13.57	Not reported	Not reported	Not reported
Nivolumab + Ipilimumab	-0.8	13.00	Not reported	Not reported	Not reported
Ipilimumab	-2.2	13.71	Not reported	Not reported	Not reported

Week 43 (n= 103, 74, 44)

Analysis denominator · Participants

Group	Source count
Nivolumab	103
Nivolumab + Ipilimumab	74
Ipilimumab	44

Values in Points on EORTC scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Nivolumab	1.9	13.16	Not reported	Not reported	Not reported
Nivolumab + Ipilimumab	-0.5	13.55	Not reported	Not reported	Not reported
Ipilimumab	-1.7	12.71	Not reported	Not reported	Not reported

Week 49 (n= 97, 70, 40)

Analysis denominator · Participants

Group	Source count
Nivolumab	97
Nivolumab + Ipilimumab	70
Ipilimumab	40

Values in Points on EORTC scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Nivolumab	1.3	12.08	Not reported	Not reported	Not reported
Nivolumab + Ipilimumab	-0.1	12.97	Not reported	Not reported	Not reported
Ipilimumab	0.2	12.31	Not reported	Not reported	Not reported

Week 55 (n= 86, 66, 34)

Analysis denominator · Participants

Group	Source count
Nivolumab	86
Nivolumab + Ipilimumab	66
Ipilimumab	34

Values in Points on EORTC scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Nivolumab	1.8	11.68	Not reported	Not reported	Not reported
Nivolumab + Ipilimumab	-2.9	13.24	Not reported	Not reported	Not reported
Ipilimumab	0.2	10.57	Not reported	Not reported	Not reported

Week 61 (n= 85, 61, 31)

Analysis denominator · Participants

Group	Source count
Nivolumab	85
Nivolumab + Ipilimumab	61
Ipilimumab	31

Values in Points on EORTC scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Nivolumab	0.2	11.65	Not reported	Not reported	Not reported
Nivolumab + Ipilimumab	-2.1	13.91	Not reported	Not reported	Not reported
Ipilimumab	-0.2	11.35	Not reported	Not reported	Not reported

Week 67 (n= 76, 61, 29)

Analysis denominator · Participants

Group	Source count
Nivolumab	76
Nivolumab + Ipilimumab	61
Ipilimumab	29

Values in Points on EORTC scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Nivolumab	0.9	12.44	Not reported	Not reported	Not reported
Nivolumab + Ipilimumab	-1.7	13.22	Not reported	Not reported	Not reported
Ipilimumab	-3.9	10.62	Not reported	Not reported	Not reported

Week 73 (n= 67, 54, 19)

Analysis denominator · Participants

Group	Source count
Nivolumab	67
Nivolumab + Ipilimumab	54
Ipilimumab	19

Values in Points on EORTC scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Nivolumab	0.5	14.38	Not reported	Not reported	Not reported
Nivolumab + Ipilimumab	-3.5	11.27	Not reported	Not reported	Not reported
Ipilimumab	-3.9	7.80	Not reported	Not reported	Not reported

Week 79 (n= 67, 54, 21)

Analysis denominator · Participants

Group	Source count
Nivolumab	67
Nivolumab + Ipilimumab	54
Ipilimumab	21

Values in Points on EORTC scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Nivolumab	-1.7	7.99	Not reported	Not reported	Not reported
Nivolumab + Ipilimumab	-4.3	17.09	Not reported	Not reported	Not reported
Ipilimumab	-1.3	6.54	Not reported	Not reported	Not reported

Week 85 (n= 68, 51, 18)

Analysis denominator · Participants

Group	Source count
Nivolumab	68
Nivolumab + Ipilimumab	51
Ipilimumab	18

Values in Points on EORTC scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Nivolumab	-1.6	12.86	Not reported	Not reported	Not reported
Nivolumab + Ipilimumab	-3.5	12.88	Not reported	Not reported	Not reported
Ipilimumab	-2.6	6.11	Not reported	Not reported	Not reported

Week 91 (n= 62, 53, 16)

Analysis denominator · Participants

Group	Source count
Nivolumab	62
Nivolumab + Ipilimumab	53
Ipilimumab	16

Values in Points on EORTC scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Nivolumab	-0.4	13.27	Not reported	Not reported	Not reported
Nivolumab + Ipilimumab	-4.2	14.45	Not reported	Not reported	Not reported
Ipilimumab	0.0	0.00	Not reported	Not reported	Not reported

Week 97 (n= 58, 49, 17)

Analysis denominator · Participants

Group	Source count
Nivolumab	58
Nivolumab + Ipilimumab	49
Ipilimumab	17

Values in Points on EORTC scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Nivolumab	-0.4	13.79	Not reported	Not reported	Not reported
Nivolumab + Ipilimumab	-4.4	16.53	Not reported	Not reported	Not reported
Ipilimumab	-0.8	4.00	Not reported	Not reported	Not reported

Week 103 (n= 53, 46, 17)

Analysis denominator · Participants

Group	Source count
Nivolumab	53
Nivolumab + Ipilimumab	46
Ipilimumab	17

Values in Points on EORTC scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Nivolumab	-1.5	17.18	Not reported	Not reported	Not reported
Nivolumab + Ipilimumab	-5.4	15.63	Not reported	Not reported	Not reported
Ipilimumab	-2.4	7.05	Not reported	Not reported	Not reported

Week 109 (n= 44, 39, 14)

Analysis denominator · Participants

Group	Source count
Nivolumab	44
Nivolumab + Ipilimumab	39
Ipilimumab	14

Values in Points on EORTC scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Nivolumab	1.7	14.74	Not reported	Not reported	Not reported
Nivolumab + Ipilimumab	-1.2	13.92	Not reported	Not reported	Not reported
Ipilimumab	-1.0	3.56	Not reported	Not reported	Not reported

Week 115 (n= 44, 36, 17)

Analysis denominator · Participants

Group	Source count
Nivolumab	44
Nivolumab + Ipilimumab	36
Ipilimumab	17

Values in Points on EORTC scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Nivolumab	0.2	14.20	Not reported	Not reported	Not reported
Nivolumab + Ipilimumab	-2.0	15.10	Not reported	Not reported	Not reported
Ipilimumab	-0.8	3.23	Not reported	Not reported	Not reported

Week 121 (n= 44, 39, 16)

Analysis denominator · Participants

Group	Source count
Nivolumab	44
Nivolumab + Ipilimumab	39
Ipilimumab	16

Values in Points on EORTC scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Nivolumab	-0.3	15.77	Not reported	Not reported	Not reported
Nivolumab + Ipilimumab	-3.4	13.58	Not reported	Not reported	Not reported
Ipilimumab	-2.5	5.37	Not reported	Not reported	Not reported

Week 127 (n= 47, 36, 17)

Analysis denominator · Participants

Group	Source count
Nivolumab	47
Nivolumab + Ipilimumab	36
Ipilimumab	17

Values in Points on EORTC scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Nivolumab	1.2	17.21	Not reported	Not reported	Not reported
Nivolumab + Ipilimumab	-3.0	16.75	Not reported	Not reported	Not reported
Ipilimumab	-2.4	5.75	Not reported	Not reported	Not reported

Week 133 (n= 29, 31, 11)

Analysis denominator · Participants

Group	Source count
Nivolumab	29
Nivolumab + Ipilimumab	31
Ipilimumab	11

Values in Points on EORTC scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Nivolumab	0.2	23.33	Not reported	Not reported	Not reported
Nivolumab + Ipilimumab	0.4	14.40	Not reported	Not reported	Not reported
Ipilimumab	-2.4	6.16	Not reported	Not reported	Not reported

Week 139 (n= 20, 19, 6)

Analysis denominator · Participants

Group	Source count
Nivolumab	20
Nivolumab + Ipilimumab	19
Ipilimumab	6

Values in Points on EORTC scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Nivolumab	0.4	7.94	Not reported	Not reported	Not reported
Nivolumab + Ipilimumab	-3.9	11.40	Not reported	Not reported	Not reported
Ipilimumab	-3.3	5.58	Not reported	Not reported	Not reported

Week 145 (n= 14, 14, 6)

Analysis denominator · Participants

Group	Source count
Nivolumab	14
Nivolumab + Ipilimumab	14
Ipilimumab	6

Values in Points on EORTC scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Nivolumab	-1.4	27.94	Not reported	Not reported	Not reported
Nivolumab + Ipilimumab	-6.7	9.06	Not reported	Not reported	Not reported
Ipilimumab	-6.7	8.43	Not reported	Not reported	Not reported

Week 151 (n= 7, 7, 1)

Analysis denominator · Participants

Group	Source count
Nivolumab	7
Nivolumab + Ipilimumab	7
Ipilimumab	1

Values in Points on EORTC scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Nivolumab	8.6	17.52	Not reported	Not reported	Not reported
Nivolumab + Ipilimumab	-9.5	12.68	Not reported	Not reported	Not reported
Ipilimumab	0.0	NA	Not reported	Not reported	No SD calculated; only one patient analyzed

Week 157 (n= 1, 3, 0)

Analysis denominator · Participants

Group	Source count
Nivolumab	1
Nivolumab + Ipilimumab	3
Ipilimumab	0

Values in Points on EORTC scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Nivolumab	0.0	NA	Not reported	Not reported	No SD calculated; only one patient analyzed
Nivolumab + Ipilimumab	-17.8	25.24	Not reported	Not reported	Not reported

Complete source fields

classes

categories
measurements
group Id
OG000
spread
13.62
value
-2.6
group Id
OG001
spread
14.52
value
-4.9
group Id
OG002
spread
14.09
value
-5.2
denoms
counts
group Id
OG000
value
233
group Id
OG001
value
183
group Id
OG002
value
221
units
Participants
title
Week 5 (n= 233, 183, 221)
categories
measurements
group Id
OG000
spread
14.53
value
-2.4
group Id
OG001
spread
14.92
value
-5.3
group Id
OG002
spread
14.69
value
-5.1
denoms
counts
group Id
OG000
value
239
group Id
OG001
value
183
group Id
OG002
value
218
units
Participants
title
Week 7 (n= 239, 183, 218)
categories
measurements
group Id
OG000
spread
16.14
value
-2.4
group Id
OG001
spread
13.76
value
-5.6
group Id
OG002
spread
14.72
value
-6.3
denoms
counts
group Id
OG000
value
201
group Id
OG001
value
112
group Id
OG002
value
163
units
Participants
title
Week 11 (n= 201, 112, 163)
categories
measurements
group Id
OG000
spread
15.79
value
-1.7
group Id
OG001
spread
14.11
value
-4.3
group Id
OG002
spread
17.47
value
-5.0
denoms
counts
group Id
OG000
value
195
group Id
OG001
value
106
group Id
OG002
value
130
units
Participants
title
Week 13 (n= 195, 106, 130)
categories
measurements
group Id
OG000
spread
15.82
value
-1.4
group Id
OG001
spread
17.27
value
-6.7
group Id
OG002
spread
13.46
value
-3.7
denoms
counts
group Id
OG000
value
158
group Id
OG001
value
84
group Id
OG002
value
104
units
Participants
title
Week 17 (n= 158, 84, 104)
categories
measurements
group Id
OG000
spread
14.14
value
0.4
group Id
OG001
spread
14.34
value
-3.7
group Id
OG002
spread
17.70
value
-4.3
denoms
counts
group Id
OG000
value
164
group Id
OG001
value
96
group Id
OG002
value
98
units
Participants
title
Week 19 (n= 164, 96, 98)
categories
measurements
group Id
OG000
spread
13.87
value
0.9
group Id
OG001
spread
15.59
value
-4.0
group Id
OG002
spread
15.04
value
-5.5
denoms
counts
group Id
OG000
value
134
group Id
OG001
value
86
group Id
OG002
value
75
units
Participants
title
Week 23 (n= 134, 86, 75)
categories
measurements
group Id
OG000
spread
11.02
value
1.4
group Id
OG001
spread
14.28
value
-4.2
group Id
OG002
spread
16.19
value
-3.6
denoms
counts
group Id
OG000
value
144
group Id
OG001
value
97
group Id
OG002
value
75
units
Participants
title
Week 25 (n= 144, 97, 75)
categories
measurements
group Id
OG000
spread
11.60
value
1.9
group Id
OG001
spread
12.91
value
-2.4
group Id
OG002
spread
14.62
value
-2.9
denoms
counts
group Id
OG000
value
123
group Id
OG001
value
92
group Id
OG002
value
51
units
Participants
title
Week 31 (n= 123, 92, 51)
categories
measurements
group Id
OG000
spread
13.57
value
2.1
group Id
OG001
spread
13.00
value
-0.8
group Id
OG002
spread
13.71
value
-2.2
denoms
counts
group Id
OG000
value
116
group Id
OG001
value
88
group Id
OG002
value
48
units
Participants
title
Week 37 (n= 116, 88, 48)
categories
measurements
group Id
OG000
spread
13.16
value
1.9
group Id
OG001
spread
13.55
value
-0.5
group Id
OG002
spread
12.71
value
-1.7
denoms
counts
group Id
OG000
value
103
group Id
OG001
value
74
group Id
OG002
value
44
units
Participants
title
Week 43 (n= 103, 74, 44)
categories
measurements
group Id
OG000
spread
12.08
value
1.3
group Id
OG001
spread
12.97
value
-0.1
group Id
OG002
spread
12.31
value
0.2
denoms
counts
group Id
OG000
value
97
group Id
OG001
value
70
group Id
OG002
value
40
units
Participants
title
Week 49 (n= 97, 70, 40)

denoms

counts
group Id
OG000
value
316
group Id
OG001
value
314
group Id
OG002
value
315
units
Participants

description

Health Related Quality of Life was assessed using the EORTC QLQ-C30 questionnaire Version 3. With the exception of 2 items included in the global health/quality of life scale, for which responses range from 1 (Very poor) to 7 (Excellent), item responses range from 1 (Not at all) to 4 (Very much). Raw scores for the EORTC QLQ-C30 are transformed to a 0-100 metric such that higher scores for all functional scales and Global Health Status indicate better HRQoL; an increase from baseline indicates improvement in HRQoL compared to baseline.

dispersion Type

Standard Deviation

groups

description
Nivolumab monotherapy 3 mg/kg intravenous (IV) once every 2 weeks (Q2W) until disease progression or unacceptable toxicity
id
OG000
title
Nivolumab
description
Nivolumab 1 mg/kg IV combined with Ipilimumab 3 mg/kg IV once every 3 weeks (Q3W) for 4 doses followed by nivolumab 3 mg/kg IV Q2W until disease progression or unacceptable toxicity
id
OG001
title
Nivolumab + Ipilimumab
description
Ipilimumab monotherapy 3 mg/kg IV Q3W for a total of 4 doses
id
OG002
title
Ipilimumab

param Type

MEAN

population Description

All randomized participants. Only participants with evaluable EORTC scores at baseline and at particular timepoint are considered in the analysis.

reporting Status

POSTED

time Frame

Baseline (Day 1) and Week 5, 7, 11, 13, 17, 19, 23, 25, 31, 37, 43, 49, 55, 61, 67, 73, 79, 85, 91, 97, 103, 109, 115, 121, 127, 133, 139, 145, 151 and 157

title

Mean Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) Physical Functioning

type

SECONDARY

unit Of Measure

Points on EORTC scale

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice